All News
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis?
@Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats)
Something to consider in these difficult-to-treat pts?
@LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU
David Liew drdavidliew ( View Tweet)
For patients on bDMARDs having surgery, we worry about post-op delayed wound healing.
In this Japanese cohort, TCZ use was a risk factor.
Unclear if meds withheld, but given IL-6 upreg in wound healing, it's plausible TCZ might have worse outcomes??
SAT0047 #EULAR2020 @RheumNow https://t.co/HVIKPplwiA
David Liew drdavidliew ( View Tweet)
So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA
Janet Pope Janetbirdope ( View Tweet)
Whom with GCA should receive tocilizumab? What happens when it is stopped? Optimal dose for maintenance weekly or Q2 weekly? GiACTA gives only some answers. Need RWE #EULAR2020 @eular_org @RheumNow @CRASCRRheum @earlyarthritis #vasculitis https://t.co/aNvR14vfEV
Janet Pope Janetbirdope ( View Tweet)
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
k dao KDAO2011 ( View Tweet)
RA pt not responding to a 1st biologic; what you predict in a Head to Head - Abatacept vs Upadacitinib?
Dr. John Cush RheumNow ( View Tweet)
#EULAR2020 #fri0505 Still’s pts who are able to achieve remissions w/longer itnervals btw tocilizumab infusions & lower dose of prednisone more likely to successfully withdraw Toci. Time to symptom recurrence in relapse group 7.8 mo. Older pts more likely to relapse @RheumNow
Olga Petryna DrPetryna ( View Tweet)
Don’t forget significant fibrosis with ILD has +RCT with nintedanib INBUILD study. Lots of buzz of RA ILD where MTX is OK, TNFi may have more ILD than other bDMARDs, biomatkers KL-6 @eular_org OP0038 #EULAR2020 @CRASCRRheum https://t.co/OihF3LmNYQ
Janet Pope Janetbirdope ( View Tweet)
#Upadacitinib #psoriaticarthritis Upa works in PsA including imaging and when they show it surprising good PASI scores as well https://t.co/ZWqj8ythHB
Peter Nash drpnash ( View Tweet)
#guselkumab #axialdisease - who would have thunk it - IL23 p19 works in axial involvement PsA with radiology! https://t.co/TaSFBJFRnx
Peter Nash drpnash ( View Tweet)
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19
Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups)
#EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
MAINRITSAN3 RCT, RTX v PLBO in AAV
28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8)
1. Selected grp (all pts from MAINRITSAN2)
2. All pts had GC q3mos - IRL benefit could be bigger?
Strong data for RTX >2yrs in AAV
PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
Mike Putman EBRheum ( View Tweet)
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
#Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM
k dao KDAO2011 ( View Tweet)
#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs
k dao KDAO2011 ( View Tweet)
